Your browser doesn't support javascript.
loading
PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.
Powers, Nicholas E; Swartzwelter, Benjamin; Marchetti, Carlo; de Graaf, Dennis M; Lerchner, Alexandra; Schlapschy, Martin; Datar, Rajiv; Binder, Uli; Edwards, Carl K; Skerra, Arne; Dinarello, Charles A.
Afiliación
  • Powers NE; Department of Medicine, University of Colorado, Aurora, Colorado 80045 nicholas.e.powers@CUAnschutz.edu.
  • Swartzwelter B; Department of Medicine, University of Colorado, Aurora, Colorado 80045.
  • Marchetti C; Department of Medicine, University of Colorado, Aurora, Colorado 80045.
  • de Graaf DM; Department of Medicine, University of Colorado, Aurora, Colorado 80045.
  • Lerchner A; Department of Internal Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
  • Schlapschy M; XL-protein GmbH, Lise-Meitner-Strasse 30, 85354 Freising, Germany.
  • Datar R; Lehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany.
  • Binder U; DNX Biopharmaceuticals, Inc., San Diego, California 92121.
  • Edwards CK; XL-protein GmbH, Lise-Meitner-Strasse 30, 85354 Freising, Germany.
  • Skerra A; DNX Biopharmaceuticals, Inc., San Diego, California 92121.
  • Dinarello CA; Lehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany.
J Biol Chem ; 295(3): 868-882, 2020 01 17.
Article en En | MEDLINE | ID: mdl-31819009
ABSTRACT
Interleukin-1 (IL-1) is a key mediator of inflammation and immunity. Naturally-occurring IL-1 receptor antagonist (IL-1Ra) binds and blocks the IL-1 receptor-1 (IL-1R1), preventing signaling. Anakinra, a recombinant form of IL-1Ra, is used to treat a spectrum of inflammatory diseases. However, anakinra is rapidly cleared from the body and requires daily administration. To create a longer-lasting alternative, PASylated IL-1Ra (PAS-IL-1Ra) has been generated by in-frame fusion of a long, defined-length, N-terminal Pro/Ala/Ser (PAS) random-coil polypeptide with IL-1Ra. Here, we compared the efficacy of two PAS-IL-1Ra molecules, PAS600-IL-1Ra and PAS800-IL-1Ra (carrying 600 and 800 PAS residues, respectively), with that of anakinra in mice. PAS600-IL-1Ra displayed markedly extended blood plasma levels 3 days post-administration, whereas anakinra was undetectable after 24 h. We also studied PAS600-IL-1Ra and PAS800-IL-1Ra for efficacy in monosodium urate (MSU) crystal-induced peritonitis. 5 days post-administration, PAS800-IL-1Ra significantly reduced leukocyte influx and inflammatory markers in MSU-induced peritonitis, whereas equimolar anakinra administered 24 h before MSU challenge was ineffective. The 6-h pretreatment with equimolar anakinra or PAS800-IL-1Ra before MSU challenge similarly reduced inflammatory markers. In cultured A549 lung carcinoma cells, anakinra, PAS600-IL-1Ra, and PAS800-IL-Ra reduced IL-1α-induced IL-6 and IL-8 levels with comparable potency. In human peripheral blood mononuclear cells, these molecules suppressed Candida albicans-induced production of the cancer-promoting cytokine IL-22. Surface plasmon resonance analyses revealed significant binding between PAS-IL-1Ra and IL-1R1, although with a slightly lower affinity than anakinra. These results validate PAS-IL-1Ra as an active IL-1 antagonist with marked in vivo potency and a significantly extended half-life compared with anakinra.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Peritonitis / Ácido Úrico / Interleucina-1 / Proteína Antagonista del Receptor de Interleucina 1 Límite: Animals / Humans Idioma: En Revista: J Biol Chem Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Peritonitis / Ácido Úrico / Interleucina-1 / Proteína Antagonista del Receptor de Interleucina 1 Límite: Animals / Humans Idioma: En Revista: J Biol Chem Año: 2020 Tipo del documento: Article